Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.41 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.41 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | NAMPT | P43490 | 1/20 | 0.38 |
| ▸ | HPGDS | O60760 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | RORC | P51449 | 1/20 | 0.38 |
| ▸ | JAK2 | O60674 | 1/20 | 0.37 |
| ▸ | JAK1 | P23458 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2328081 | 0.89 | HPGDS (0.49) | KDM4EEPHX1MAPTTHRBNAMPT | |
| SCHEMBL8405112 | 0.88 | HPGDS (0.50) | KDM4EEPHX1MAPTTHRBHPGDS | |
| SCHEMBL459905 | 0.86 | MAPT (0.51) | KDM4EEPHX1MAPTTHRBNAMPT | |
| SCHEMBL28934785 | 0.86 | NR1H2 (0.40) | KDM4ENR1H2DDB1CRBNMAPT | |
| SCHEMBL30241680 | 0.86 | NR1H2 (0.40) | KDM4ENR1H2DDB1CRBNMAPT | |
| SCHEMBL31000675 | 0.77 | PTPN1 (0.39) | NR1H2JAK2JAK1 | |
| SCHEMBL10254819 | 0.77 | PTPN1 (0.39) | NR1H2JAK2JAK1 | |
| SCHEMBL1357636 | 0.77 | ALDH1A1 (0.49) | MAPTMEN1KMT2A | |
| SCHEMBL1357634 | 0.77 | ALDH1A1 (0.49) | MAPTMEN1KMT2A | |
| SCHEMBL27034260 | 0.76 | KDM4E (0.41) | KDM4ENR1H2DDB1CRBNMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4559911-A1 | NOVEL HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION FOR INHIBITING AUTOTAXIN COMPRISING THE SAME | Nextgen Bioscience Co., Ltd. (KR) | 2025-05-28 | — | — | EP | disclosed |
| WO-2024019597-A1 | NOVEL HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION FOR INHIBITING AUTOTAXIN COMPRISING THE SAME | 주식회사 넥스트젠바이오사이언스 | 2024-01-25 | — | — | WO | disclosed |
| US-20230381177-A1 | INHIBITORS OF ALPHA-AMINO-BETA-CARBOXYMUCONIC ACID SEMIALDEHYDE DECARBOXYLASE | TES PHARMA S.R.L. (IT) | 2023-11-30 | — | — | US | disclosed |
| US-20210379069-A1 | INHIBITORS OF ALPHA-AMINO-BETA-CARBOXYMUCONIC ACID SEMIALDEHYDE DECARBOXYLASE | TES PHARMA S R L (IT) | 2021-12-09 | — | — | US | disclosed |
| EP-2305660-A1 | New thiadiazole derivatives | Almirall, S.A. (ES) | 2011-04-06 | — | — | EP | disclosed |
| WO-2011035900-A1 | NEW THIADIAZOLE DERIVATIVES | ALMIRALL, S.A. (ES) | 2011-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230381177-A1 | INHIBITORS OF ALPHA-AMINO-BETA-CARBOXYMUCONIC ACID SEMIALDEHYDE DECARBOXYLASE | ACMSD, GLS, ALDH7A1 | KDM4E 1110/4885NR1H2 3493/4885DDB1 2340/4885 |
| US-20210379069-A1 | INHIBITORS OF ALPHA-AMINO-BETA-CARBOXYMUCONIC ACID SEMIALDEHYDE DECARBOXYLASE | ACMSD, GLS, ALDH7A1 | KDM4E 1110/4885NR1H2 3493/4885DDB1 2340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.